Patent 7390795 was granted and assigned to Pentraxin Therapeutics Limited on June, 2008 by the United States Patent and Trademark Office.
A method for the treatment or prevention of tissue damage in a subject having an inflammatory and/or tissue damaging condition, which comprises administering to the subject an effective amount of a compound capable of inhibiting the binding of C-reactive protein (CRP) to an autologous or extrinsic ligand.